H.C. Wainwright maintains buy rating on Invivyd stock after positive data

Investing.com - H.C. Wainwright has reiterated its buy rating and $5.00 price target on Invivyd Inc. (NASDAQ:IVVD), a $84.5 million market cap biotech company with impressive 93% gross margins, following positive Phase 1/2 data for the company’s COVID-19 antibody treatment. According to InvestingPro data, analyst targets for the stock range from $0.80 to $9.00.

The research firm highlighted data released Wednesday for VYD2311, Invivyd’s next-generation monoclonal antibody designed for both prevention and treatment of COVID-19, noting its long half-life, favorable safety profile, and flexible administration options.

According to the trial results, VYD2311 was well tolerated across intravenous, intramuscular, and subcutaneous administration routes, with no serious adverse events reported and a half-life of up to 76 days for intramuscular dosing.

H.C. Wainwright believes these results position VYD2311 as a potential best-in-class prophylactic and treatment option with broad utility, particularly via intramuscular administration.

The firm views Wednesday’s update as a meaningful de-risking event for Invivyd’s platform, with a Type C FDA meeting scheduled for early third quarter 2025 to discuss next steps toward registration.

In other recent news, Invivyd Inc. reported its Q1 2025 earnings, revealing a net product revenue of $11.3 million from its COVID-19 prevention product, PEMGARDA. Despite a 15% reduction in operating expenses, the company’s earnings per share and revenue fell short of forecasts. Analysts at H.C. Wainwright reduced their price target for Invivyd shares to $5.00 from $10.00 but maintained a Buy rating, citing potential catalysts for near-term value. Invivyd’s next-generation monoclonal antibody candidate, VYD2311, demonstrated a favorable safety profile in a Phase 1/2 clinical trial, maintaining high serum concentrations for six months. The company plans to discuss approval pathways with the FDA for its COVID-19 monoclonal antibodies. Additionally, Invivyd’s monoclonal antibody PEMGARDA has been incorporated into the National Comprehensive Cancer Network® Clinical Practice Guidelines for B-Cell Lymphomas, offering a preventive option for patients with B-cell malignancies. Invivyd is also expanding its discovery programs to include targets for measles and respiratory syncytial virus (RSV). These developments indicate a strategic shift towards establishing a broad-based antibody platform for infectious diseases.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.